ELAB PMGC HOLDINGS INC.

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC,” “our,” or “we”) (Nasdaq: ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group’s (“TCA”) Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence.

TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-stage and seed-stage companies across all innovation-driven industries. Since its founding in 1997, TCA members have invested over $300 million in more than 525 companies, attracting an additional $2.2 billion in follow-on investments, primarily from venture capital firms.

“We are excited to join forces with TCA Venture Group as a key sponsor,” said Graydon Bensler, CFA, Chief Executive Officer of PMGC. “This sponsorship aligns perfectly with our mission to identify and support high-potential companies, providing both capital and operational expertise to drive long-term growth. TCA’s vast network of investors, entrepreneurs, and industry experts will enhance our ability to expand our portfolio and execute our acquisition strategy while directly contributing to the thriving Southern California business ecosystem.”

PMGC currently manages and operates a diverse portfolio of three wholly owned subsidiaries:

  • NorthStrive Biosciences Inc. – A biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www..
  • PMGC Research Inc. – A research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian universities to accelerate scientific discovery and transform cutting-edge technologies into commercially viable products.
  • PMGC Capital LLC. – A multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. The company’s mission is to identify and seize high-potential opportunities, delivering sustainable growth and maximizing returns on capital.

Through this sponsorship, PMGC will gain valuable exposure through TCA’s national network, engage with over 400 seasoned investors, business leaders, and industry professionals. TCA members, consisting of experienced C-level executives, entrepreneurs, venture capitalists, and other professionals, not only invest in early-stage companies but also provide hands-on mentorship, board representation, and strategic partnerships. TCA is one of the largest and most active angel investor groups nationally, consistently ranking in the top three for deals funded, amounts invested, and membership size. The HALO Report recently ranked TCA as # 2 U.S. angel investment network for funded deals, and CB Insights, a market intelligence platform, has recognized TCA as the top-ranked angel group in terms of network centrality.

By aligning with TCA, PMGC strengthens its commitment to fostering entrepreneurial success and supporting innovative businesses. The Company believes this collaboration will open doors to new investment opportunities and further enhance PMGC’s position as a leading player in the investment and M&A landscape.

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit .

About TCA Venture Group

TCA Venture Group is one of the largest and most active angel investor networks in the nation, and a leading source of funding for seed-stage and early-stage companies across all innovation industries in Southern California. TCA members are accredited investors who individually invest in startup companies. Companies go through well-structured, transparent, and time efficient screening and due diligence. As founders and executive-level business leaders, TCA members provide companies with more than just capital; they also contribute counsel, mentoring and access to an extensive network of investors, customers, strategic partners and management. TCA is a catalyst in the growth of the thriving Southern California entrepreneurial ecosystem of innovation. Since its founding in 1997, TCA has invested over $218 million in more than 380 companies and has helped attract more than $1.66 billion in additional capital/follow-on rounds, mostly from venture capital firms.

Learn more at www..

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at . All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact:



EN
27/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PMGC HOLDINGS INC.

 PRESS RELEASE

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Fi...

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GL...

 PRESS RELEASE

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Follo...

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial NEWPORT BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), is proud to announce that Co-Founder Deniel Mero was recently featured in an exclusive interview hosted by Bear Bull Traders, a leading global online stock trading community for professional and aspiring traders. During the ...

 PRESS RELEASE

Northstrive Biosciences Announces Positive FDA Response Supporting A S...

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists.Northstrive believes the FDA responses encourage a path forward for filing an IND application to conduct a Phase 2 clinical trial in overweight or obese patients.EL-22 is leveraging a myo...

 PRESS RELEASE

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-B...

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company Acquisition Target Currently Serves over 300 Commercial Clients, which Includes Data Centers, Technology Manufacturers, and IT Service Providers with Close to 15 Years of Operational History, 90% U.S.-Based Revenue, and Recurring Business NEWPORT BEACH, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: PMGC) (the “Company,” “PMGC,” “we,” or “us”), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) to a...

 PRESS RELEASE

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Dev...

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases Northstrive Biosciences and Yuva Biosciences’ collaboration will leverage MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Northstrive and Yuva Biosciences will compile a library of small molecule candidates that promote mitochondrial health and target the root cause of aging at the cellul...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch